繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 上市新药 >> MOZOBIL(plerixafor injection 中文药名 普乐沙福注射剂)

MOZOBIL(plerixafor injection 中文药名 普乐沙福注射剂)

2012-07-29 03:41:17  作者:新特药房  来源:中国新特药网天津分站  浏览次数:389  文字大小:【】【】【
简介: 美国FDA 批准基Genzyme公司的plerixafor注射液(Mozobil)上市,与粒细胞集落刺激因子(G-CSF)联合用药促进红细胞生成素干细胞进入非霍奇金淋巴瘤(NHL)和多发性骨髓瘤(MM)患者血流以收集、随后自 ...

美国FDA批准基Genzyme公司的plerixafor注射液(Mozobil)上市,与粒细胞集落刺激因子(G-CSF)联合用药促进红细胞生成素干细胞进入非霍奇金淋巴瘤(NHL)和多发性骨髓瘤(MM)患者血流以收集、随后自体移植。
本品还被获准作为罕用药物。
剂量规格:普乐沙福20 mg/mL。
本品系一新颖的小分子CXCR4趋化因子受体阻断剂,在多项早期研究显示可快速有效地增加NHL和MM患者血液循环中的干细胞数。
本品在治疗需干细胞移植的某些类型癌症患者是一重大进展。由于本品有益于患者、医生和移植治疗中心将成为干细胞移植治疗方案的整体部分。
本品调动红细胞生成素干细胞从骨髓进入血流,收集、为需干细胞移植的某些类型癌症患者进行移植。以往,移植前患者需接受处方药化疗和(或)生长因子类药物来帮助其调动红细胞生成素干细胞进入血流。一旦此细胞进入血流,它们被收集用于移植制备。
为了完成干细胞移植,按体重必需收集约200万个干细胞/kg。许多患者需3~4小时至数日来完成此过程。甚至一些患者调动不了足够的干细胞,因而不能进行移植。对许多癌症患者来说,调动干细胞是缩小癌症或治愈的唯一希望。
在本品关键的临床研究中,59%的NHL患者接受本品和G-CSF联合用药治疗旨在4个或更少的单采血液成分术期间内按体重至少收集的目标数为500万个干细胞/kg,与20%接受安慰剂的患者进行比较。
Mozobil治疗组达到目标细胞数的平均天数为3日,安慰剂组未作评价。72%的MM患者接受Mozobil与G-CSF联合用药治疗旨在2个或更少的单采血液成分术期间内按体重至少收集的目标数为600万个干细胞/kg,与28%使用安慰剂患者进行对照。
本品组达到靶细胞数的平均天数为1日,安慰剂组为4日。
在关键的临床研究中选择的干细胞目标数是依据达到这些目标数有助于促进移植的文献资料。
本品可减少单采血液成分术的天数,可向移植中心提供可预测和有效地使用单采血液成分术中心。本品还可减少原先单一采用G-CSF治疗不能调动足够细胞数需第2次治疗的患者人数。
Mozobil是一种造血干细胞激活剂以及CXCR4趋化因子拮抗剂。CXXR4属于特异性的基质细胞衍生因子1(SDF-1),SDF-1具有潜在的淋巴细胞趋化活性。
由于SDF-1与CXCR4之间的相互作用对于造血干细胞停留在骨髓内具有非常重要的作用,所以能够阻断CXCR4受体的药物应该具有“动员”造血干细胞“释放”入血液的能力。Mozobil与粒细胞集落刺激因子(G-CSF)联合应用可将造血干细胞释放入周围血液中,收集后即可用于非霍奇金淋巴瘤和多发性骨髓瘤患者的自体移植。
Mozobil的剂型是注射液,用于皮下注射。接受Mozobil治疗前,患者需先给予G-CSF每天一次共4天。Mozobil最迟要在进行干细胞分离之前大约11个小时使用,最长可连续给药4天。推荐初始剂量为0.24 mg/kg,皮下注射。剂量不能超过40 mg/d。对于有中到重度肾损伤的患者(肌酐清除率 =50 mL/ min),Mozobil的剂量要减1/3,降到0.16 mg/kg。
FDA批准Mozobil上市是基于两项安慰剂对照临床研究的结果。两项研究中,均将患者分为两组,在进行干细胞分离的前一晚随机给予Mozobil 0.24mg/kg或安慰剂。
在首次给予Mozobil或安慰剂前以及进行干细胞分离的每个早上给予G-CSF 10 mg/kg共4天。
第一项研究:
共入组298例非霍奇金淋巴瘤患者。结果表明,给予Mozobil和G-CSF联合治疗的患者,有59%的患者的外周血中可收集到≥5×106的CD34+ cells/kg,而用安慰剂和G-CSF的患者只有20%可收集到(P <0.001)。Mozobil组收集到5×106的CD34+ cells/kg的中位天数为3天。而安慰剂组没有达到中位时间。
第二项研究:
入组了302例多发性多发性骨髓瘤患者。结果表明,给予Mozobil和G-CSF联合治疗的患者,有72%的患者可在外周血中收集到≥6×106的CD34+ cells/kg,而用安慰剂和G-CSF的患者只有34%可收集到(P <0.001)。
Mozobil组收集到6×106的CD34+ cells/kg的中位天数为1天,安慰剂组为4天。
有关Mozobil长期安全性和有效性的研究正在进行中(3101-LTF),将历时5年,对患者的死亡结局以及疾病状态(复发或无病生存)进行评价。
不良反应主要包括:腹泻、恶心、乏力、注射部位反应、头痛、关节痛、头昏、呕吐等。
该药是一种造血干(祖)细胞激活剂,同时可刺激造血干(祖)细胞增殖、分化进入血液循环的功能。
多项试验研究证明Mozobil在粒细胞刺激因子(G-CSF)或粒单核细胞刺激因子(GM-CSF)联合作用下,可使造血干(祖)细胞增殖,释放入外周血中的数量明显增多,使末梢血CD34+细胞群和造血祖细胞集落增加,可使自体造血干细胞移植的成功率明显增加。
由于非霍奇金淋巴瘤(NHL)和多发性骨髓瘤(MM)大部分缓解病例和进展病例需进行末梢血自体造血干细胞移植,而Mozobil联合G-CSF又能明显提高患者外周血中CD34+细胞的数量,大约可使60%病人的外周血CD34+细胞增加,保证了NHL和MM患者自体造血干细胞移植的成功。


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use MOZOBIL safely and effectively. See full prescribing information for MOZOBIL.
MOZOBIL (plerixafor injection), Solution for Subcutaneous use
Initial U.S. Approval: 2008
INDICATIONS AND USAGE
Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma. (1)
DOSAGE AND ADMINISTRATION
• Initiate Mozobil treatment after the patient has received G-CSF once daily for 4 days. (2.1)
• Repeat Mozobil dose up to 4 consecutive days. (2.1)
• Select dose based on 0.24 mg/kg actual body weight. (2.1)
• Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. (2.1)
• Renal impairment:  If creatinine clearance is ≤ 50 mL/min, decrease dose by one-third to 0.16 mg/kg. (2.3)
DOSAGE FORMS AND STRENGTHS
• Single-use vial containing 1.2 mL of a 20 mg/mL solution. (3)
CONTRAINDICATIONS
• None. (4)
WARNINGS AND PRECAUTIONS
Tumor Cell Mobilization in Leukemia Patients: Mozobil may mobilize leukemic cells and should not be used in leukemia patients. (5.1)
Hematologic Effects: Increased circulating leukocytes and decreased platelet counts have been observed.  Monitor blood cell counts and platelet counts during Mozobil use. (5.2)
Potential for Tumor Cell Mobilization:  Tumor cells may be released from marrow during HSC mobilization with Mozobil and G-CSF.  Effect of reinfusion of tumor cells is unknown. (5.3)
Potential for Splenic Rupture: Evaluate patients who report left upper abdominal and/or scapular or shoulder pain. (5.4)
Pregnancy: May cause fetal harm.  Advise women not to become pregnant when taking Mozobil.  (5.5, 8.1)
ADVERSE REACTIONS
Most common adverse reactions (≥ 10%): diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-877-4MOZOBIL or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 8/2009
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
Mozobil® (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). 
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage and Administration
Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.
Begin treatment with Mozobil after the patient has received G-CSF once daily for four days. [see Dosage and Administration (2.2)]  Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.
The recommended dose of Mozobil is 0.24 mg/kg body weight by subcutaneous (SC) injection. Use the patient’s actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:
0.012 X patient’s actual body weight (in kg) = volume to be administered (in mL)
In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
Based on increasing exposure with increasing body weight, the plerixafor dose should not exceed 40 mg/day. [see Clinical Pharmacology (12.3)] 
2.2 Recommended Concomitant Medications
Administer daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first evening dose of Mozobil and on each day prior to apheresis. [see Clinical Studies (14)]
2.3 Dosing in Renal Impairment
In patients with moderate and severe renal impairment (estimated creatinine clearance (CLCR) ≤ 50 mL/min), reduce the dose of Mozobil by one-third to 0.16 mg/kg as shown in Table 1. If CLCR is ≤ 50 mL/min the dose should not exceed 27 mg/day, as the mg/kg-based dosage results in increased plerixafor exposure with increasing body weight. [see Clinical Pharmacology (12.3)]  Similar systemic exposure is predicted if the dose is reduced by one-third in patients with moderate and severe renal impairment compared with subjects with normal renal function. [see Clinical Pharmacology (12.3)] 
Table 1: Recommended Dosage of Plerixafor in Patients with Renal Impairment

Estimated Creatinine Clearance    
(mL/min)
Dose
> 50     0.24 mg/kg once daily (not to exceed 40 mg/day)     
≤ 50     0.16 mg/kg once daily (not to exceed 27 mg/day)
The following (Cockroft-Gault) formula may be used to estimate CLCR: 
Males:
Creatinine clearance (mL/min) = weight (kg) X (140 – age in years)
72 X serum creatinine (mg/dL)
Females:
Creatinine clearance (mL/min) = 0.85 X value calculated for males
There is insufficient information to make dosage recommendations in patients on hemodialysis.
3 DOSAGE FORMS AND STRENGTHS
Single-use vial containing 1.2 mL of a 20 mg/mL solution.
4 CONTRAINDICATIONS
None
5 WARNINGS AND PRECAUTIONS
5.1 Tumor Cell Mobilization in Leukemia Patients
For the purpose of HSC mobilization, Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for HSC mobilization and harvest in patients with leukemia.
5.2 Hematologic Effects
Leukocytosis
Administration of Mozobil in conjunction with G-CSF increases circulating leukocytes as well as HSC populations. Monitor white blood cell counts during Mozobil use. Exercise clinical judgment when administering Mozobil to patients with peripheral blood neutrophil counts above 50,000/mcL.
Thrombocytopenia
Thrombocytopenia has been observed in patients receiving Mozobil. Monitor platelet counts in all patients who receive Mozobil and then undergo apheresis.
5.3 Potential for Tumor Cell Mobilization
When Mozobil is used in combination with G-CSF for HSC mobilization‚ tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.
5.4 Splenic Enlargement and Potential for Rupture
Higher absolute and relative spleen weights associated with extramedullary hematopoiesis were observed following prolonged (2 to 4 weeks) daily plerixafor SC administration in rats at doses approximately 4-fold higher than the recommended human dose based on body surface area. The effect of Mozobil on spleen size in patients was not specifically evaluated in clinical studies. Evaluate individuals receiving Mozobil in combination with G-CSF who report left upper abdominal pain and/or scapular or shoulder pain for splenic integrity.
5.5 Pregnancy
Pregnancy Category D
Mozobil may cause fetal harm when administered to a pregnant woman. Plerixafor was teratogenic in animals. There are no adequate and well-controlled studies in pregnant women using Mozobil. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. [see Use In Specific Populations (8.1)]
6 ADVERSE REACTIONS
6.1 Clinical Trial Experience
The following serious adverse reactions are discussed elsewhere in the labeling:
Potential for tumor cell mobilization in leukemia patients [see Warnings and Precautions (5.1)]
Increased circulating leukocytes and decreased platelet counts [see Warnings and Precautions (5.2)]
Potential for splenic enlargement [see Warnings and Precautions (5.4)]
The most common adverse reactions (≥ 10%) reported in patients who received Mozobil in conjunction with G-CSF regardless of causality and more frequent with Mozobil than placebo during HSC mobilization and apheresis were diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting.
Safety data for Mozobil in combination with G-CSF were obtained from two randomized placebo-controlled studies (301 patients) and 10 uncontrolled studies (242 patients). Patients were primarily treated with Mozobil at daily doses of 0.24 mg/kg SC. Median exposure to Mozobil in these studies was 2 days (range 1 to 7 days).
In the two randomized studies in patients with NHL and MM, a total of 301 patients were treated in the Mozobil and G-CSF group and 292 patients were treated in the placebo and G-CSF group. Patients received daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first dose of Mozobil 0.24 mg/kg SC or placebo and on each morning prior to apheresis. The adverse reactions that occurred in ≥ 5% of the patients who received Mozobil regardless of causality and were more frequent with Mozobil than placebo during HSC mobilization and apheresis are shown in Table 2. 
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Table 2: Adverse Reactions in ≥ 5% of Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients Receiving Mozobil® and More Frequent than Placebo During HSC Mobilization and Apheresis

Percent of Patients (%)
   Mozobil® and G-CSF
(n = 301)
Placebo and G-CSF
(n = 292)
  All
Grades  
Grade
3
Grade
4
All
Grades
Grade
3
Grade
4

 

Gastrointestinal disorders            
    Diarrhea  37 < 1 0 17 0 0
    Nausea 34 1 0 22 0 0
    Vomiting     10 < 1 0 6 0 0
    Flatulence 7 0 0 3 0 0
General disorders and administration site conditions            
    Injection site reactions         34 0 0 10 0 0
    Fatigue  27 0 0 25 0 0
Musculoskeletal and connective tissue disorders                
    Arthralgia  13 0 0 12 0 0
Nervous system disorders            
    Headache 22 < 1 0 21 1 0
    Dizziness 11 0 0 6 0 0
Psychiatric disorders            
   Insomnia 7 0 0 5 0 0
Grades based on criteria from the World Health Organization (WHO)
In the randomized studies, 34% of patients with NHL or MM had mild to moderate injection site reactions at the site of subcutaneous administration of Mozobil. These included erythema, hematoma, hemorrhage, induration, inflammation, irritation, pain, paresthesia, pruritus, rash, swelling, and urticaria.
Mild to moderate systemic reactions were observed in less than 1% of patients approximately 30 min after Mozobil administration. Events included one or more of the following: urticaria (n = 2), periorbital swelling (n = 2), dyspnea (n = 1) or hypoxia (n = 1). Symptoms generally responded to treatments (e.g., antihistamines, corticosteroids, hydration or supplemental oxygen) or resolved spontaneously.
Vasovagal reactions, orthostatic hypotension, and/or syncope can occur following subcutaneous injections. In Mozobil oncology and healthy volunteer clinical studies, less than 1% of subjects experienced vasovagal reactions following subcutaneous administration of Mozobil doses ≤ 0.24 mg/kg. The majority of these events occurred within 1 hour of Mozobil administration. Because of the potential for these reactions, appropriate precautions should be taken.
Other adverse reactions in the randomized studies that occurred in < 5% of patients but were reported as related to Mozobil during HSC mobilization and apheresis included abdominal pain, hyperhidrosis, abdominal distention, dry mouth, erythema, stomach discomfort, malaise, hypoesthesia oral, constipation, dyspepsia, and musculoskeletal pain.
7 DRUG INTERACTIONS
Based on in vitro data, plerixafor is not a substrate, inhibitor or inducer of human cytochrome P450 isozymes. Plerixafor is not likely to be implicated in in vivo drug-drug interactions involving cytochrome P450s. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study. [see Clinical Pharmacology (12.3)]
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category D
Plerixafor was teratogenic in animals. Plerixafor administered to pregnant rats induced embryo-fetal toxicities including fetal death, increased resorptions and post-implantation loss, decreased fetal weights, anophthalmia, shortened digits, cardiac interventricular septal defect, ringed aorta, globular heart, hydrocephaly, dilatation of olfactory ventricles, and retarded skeletal development. Embryo-fetal toxicities occurred mainly at a dose of 90 mg/m2 (approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m2 basis or 10 times the AUC in subjects with normal renal function who received a single dose of 0.24 mg/kg).
8.3 Nursing Mothers
It is not known whether plerixafor is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Mozobil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
The safety and efficacy of Mozobil in pediatric patients have not been established in controlled clinical studies.
8.5 Geriatric Use
Of the total number of subjects in controlled clinical studies of Mozobil, 24% were 65 and over, while 0.8% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Since plerixafor is mainly excreted by the kidney, no dose modifications are necessary in elderly individuals with normal renal function.  In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age.  Dosage adjustment in elderly patients with CLCR ≤ 50 mL/min is recommended. [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]
8.6 Renal Impairment
In patients with moderate and severe renal impairment (CLCR ≤ 50 mL/min), reduce the dose of plerixafor by one-third to 0.16 mg/kg. [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)] 
10 OVERDOSAGE
Based on limited data at doses above the recommended dose of 0.24 mg/kg SC, the frequency of gastrointestinal disorders, vasovagal reactions, orthostatic hypotension, and/or syncope may be higher.
11 DESCRIPTION
Mozobil (plerixafor injection) is a sterile, preservative-free, clear, colorless to pale yellow, isotonic solution for subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor.  Each single-use vial is filled to deliver 1.2 mL of the sterile solution that contains 24 mg of plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if required. 
Plerixafor is a hematopoietic stem cell mobilizer with a chemical name 1, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane.  It has the molecular formula C28H54N8.  The molecular weight of plerixafor is 502.79 g/mol. The structural formula is provided in Figure 1.
Figure 1: Structural Formula


Plerixafor is a white to off-white crystalline solid.  It is hygroscopic. Plerixafor has a typical melting point of 131.5 °C. The partition coefficient of plerixafor between 1-octanol and pH 7 aqueous buffer is < 0.1.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α).  SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans.  CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models.
12.2 Pharmacodynamics
Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day were evaluated in two placebo-controlled clinical studies in patients with NHL and MM (Study 1 and Study 2, respectively). The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis is summarized in Table 3.  During this 24-hour period, a single dose of Mozobil or placebo was administered 10 to 11 hours prior to apheresis.
Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with G-CSF and Administration of Plerixafor

Study Mozobil® and G-CSF Placebo and G-CSF
   Median  Mean (SD)   Median    Mean (SD)
 Study 1  5.0  6.1 (5.4)  1.4  1.9 (1.5)
 Study 2  4.8  6.4 (6.8)  1.7  2.4 (7.3)
In pharmacodynamic studies of Mozobil in healthy volunteers, peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. In pharmacodynamic studies of Mozobil in conjunction with G-CSF in healthy volunteers, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.
12.3 Pharmacokinetics
The single-dose pharmacokinetics of plerixafor 0.24 mg/kg were evaluated in patients with NHL and MM following pre-treatment with G-CSF (10 micrograms/kg once daily for 4 consecutive days).  Plerixafor exhibits linear kinetics between the 0.04 mg/kg to 0.24 mg/kg dose range.  The pharmacokinetics of plerixafor were similar across clinical studies in healthy subjects who received plerixafor alone and NHL and MM patients who received plerixafor in combination with G-CSF.
A population pharmacokinetic analysis incorporated plerixafor data from 63 subjects (NHL patients, MM patients, subjects with varying degrees of renal impairment, and healthy subjects) who received a single SC dose (0.04 mg/kg to 0.24 mg/kg) of plerixafor.  A two-compartment disposition model with first order absorption and elimination was found to adequately describe the plerixafor concentration-time profile. Significant relationships between clearance and creatinine clearance (CLCR), as well as between central volume of distribution and body weight were observed.  The distribution half-life (t1/2α) was estimated to be 0.3 hours and the terminal population half-life (t1/2β) was 5.3 hours in patients with normal renal function.
The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC0-24h) with increasing body weight.  There is limited experience with the 0.24 mg/kg dose of plerixafor in patients weighing above 160 kg.  Therefore the dose should not exceed that of a 160 kg patient (i.e., 40 mg/day if CLCR is > 50 mL/min and 27 mg/day if CLCR is ≤ 50 mL/min).  [see Dosage and Administration (2.1, 2.3)]
Absorption
Peak plasma concentrations occurred at approximately 30 - 60 minutes after a SC dose.
Distribution
Plerixafor is bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 L/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space.
Metabolism
The metabolism of plerixafor was evaluated with in vitro assays.  Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6, and 3A4/5). In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in cytochrome P450-dependent drug-drug interactions.
Elimination
The major route of elimination of plerixafor is urinary. Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted in the urine as the parent drug during the first 24 hours following administration. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study with MDCKII and MDCKII-MDR1 cell models.
Renal Impairment
Following a single 0.24 mg/kg SC dose, plerixafor clearance was reduced in subjects with varying degrees of renal impairment and was positively correlated with CLCR.  The mean AUC0-24h of plerixafor in subjects with mild (CLCR 51-80 mL/min), moderate (CLCR 31-50 mL/min), and severe (CLCR < 31 mL/min) renal impairment was 7%, 32%, and 39% higher than healthy subjects with normal renal function, respectively.  Renal impairment had no effect on Cmax. A population pharmacokinetic analysis indicated an increased exposure (AUC0-24h) in patients with moderate and severe renal impairment compared to patients with CLCR > 50 mL/min. These results support a dose reduction of one-third in patients with moderate to severe renal impairment (CLCR ≤ 50 mL/min) in order to match the exposure in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC0-24h) with increasing body weight; therefore if CLCR is ≤ 50 mL/min the dose should not exceed 27 mg/day.  [see Dosage and Administration (2.3)]
Since plerixafor is primarily eliminated by the kidneys, coadministration of plerixafor with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor or the coadministered drug.  The effects of coadministration of plerixafor with other drugs that are renally eliminated or are known to affect renal function have not been evaluated.
Race
Clinical data show similar plerixafor pharmacokinetics for Caucasians and African-Americans, and the effect of other racial/ethnic groups has not been studied. 
Gender
Clinical data show no effect of gender on plerixafor pharmacokinetics.
Age
Clinical data show no effect of age on plerixafor pharmacokinetics.
12.4 QT/QTc Prolongation
There is no indication of a QT/QTc prolonging effect of Mozobil in single doses up to 0.40 mg/kg. In a randomized, double-blind, crossover study, 48 healthy subjects were administered a single subcutaneous dose of Mozobil (0.24 mg/kg and 0.40 mg/kg) and placebo. Peak concentrations for 0.40 mg/kg Mozobil were approximately 1.8-fold higher than the peak concentrations following the 0.24 mg/kg single subcutaneous dose.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies with plerixafor have not been conducted.
Plerixafor was not genotoxic in an in vitro bacterial mutation assay (Ames test in Salmonella), an in vitro chromosomal aberration test using V79 Chinese hamster cells, or an in vivo bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg (150 mg/m2).
The effect of plerixafor on human fertility is unknown.  The effect of plerixafor on male or female fertility was not studied in designated reproductive toxicology studies.  The staging of spermatogenesis measured in a 28-day repeated dose toxicity study in rats revealed no abnormalities considered to be related to plerixafor.  No histopathological evidence of toxicity to male or female reproductive organs was observed in 28-day repeated dose toxicity studies.
14 CLINICAL STUDIES
The efficacy and safety of Mozobil in conjunction with G-CSF in non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) were evaluated in two placebo-controlled studies (Studies 1 and 2).  Patients were randomized to receive either Mozobil 0.24 mg/kg or placebo on each evening prior to apheresis. Patients received daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first dose of Mozobil or placebo and on each morning prior to apheresis. Two hundred and ninety-eight (298) NHL patients were included in the primary efficacy analyses for Study 1. The mean age was 55.1 years (range 29-75) and 57.5 years (range 22-75) in the Mozobil and placebo groups, respectively, and 93% of subjects were Caucasian. Three hundred and two (302) MM patients were included in the primary efficacy analyses for Study 2. The mean age was 58.2 years (range 28-75) and 58.5 years (range 28-75) in the Mozobil and placebo groups, respectively, and 81% of subjects were Caucasian.
In Study 1, 59% of NHL patients who were mobilized with Mozobil and G-CSF collected ≥ 5 X 106 CD34+ cells/kg from the peripheral blood in four or fewer apheresis sessions, compared with 20% of patients who were mobilized with placebo and G-CSF (p < 0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 4). 
Table 4: Study 1 Efficacy Results - CD34+ Cell Mobilization in NHL Patients

 Efficacy Endpoint Mozobil® and
G-CSF
(n = 150)
Placebo and
G-CSF
(n = 148)
p-value  

 

Patients achieving ≥ 5 X 106 cells/kg in ≤ 4 apheresis days 89 (59%) 29 (20%) < 0.001
Patients achieving ≥ 2 X 106 cells/kg in ≤ 4 apheresis days 130 (87%) 70 (47%) < 0.001
p-value calculated using Pearson's Chi-Squared test
The median number of days to reach ≥ 5 x 106 CD34+ cells/kg was 3 days for the Mozobil group and not evaluable for the placebo group. Table 5 presents the proportion of patients who achieved ≥ 5 x 106 CD34+ cells/kg by apheresis day.
Table 5: Study 1 Efficacy Results - Proportion of Patients Who Achieved ≥ 5 x 106 CD34+ cells/kg by Apheresis Day in NHL Patients

Days Proportion  
in Mozobil® and G-CSF
(n=147)
 Proportion  
in Placebo and G-CSF
(n = 142)

 

1 27.9% 4.2%
2 49.1% 14.2%
3 57.7% 21.6%
4 65.6% 24.2%
Percents determined by Kaplan Meier method
n includes all patients who received at least one day of apheresis
In Study 2, 72% of MM patients who were mobilized with Mozobil and G-CSF collected ≥ 6 X 106 CD34+ cells/kg from the peripheral blood in two or fewer apheresis sessions, compared with 34% of patients who were mobilized with placebo and G-CSF (p < 0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 6). 
Table 6: Study 2 Efficacy Results - CD34+ Cell Mobilization in Multiple Myeloma Patients

Efficacy Endpoint     Mozobil® and
G-CSF
(n=148)
Placebo and
G-CSF
(n=154)
  p-value 
Patients achieving ≥ 6 X 106 cells/kg in ≤ 2 apheresis days  106 (72%)  53 (34%)  < 0.001
Patients achieving ≥ 6 X 106 cells/kg in ≤ 4 apheresis days   112 (76%) 79 (51%)  < 0.001
Patients achieving ≥ 2 X 106 cells/kg in ≤ 4 apheresis days    141 (95%)  136 (88%)  0.028
p-value calculated using Pearson's Chi-Squared test
The median number of days to reach ≥ 6 x 106 CD34+ cells/kg was 1 day for the Mozobil group and 4 days for the placebo group. Table 7 presents the proportion of patients who achieved ≥ 6 x 106 CD34+ cells/kg by apheresis day.
Table 7: Study 2 – Proportion of Patients Who Achieved ≥ 6 x 106 CD34+ cells/kg by Apheresis Day in MM Patients

Days  Proportion  
in Mozobil® and G-CSF
(n=144) 
 Proportion  
in Placebo and G-CSF
(n=150)

 

 1  54.2%  17.3%
 2  77.9%  35.3%
 3  86.8%  48.9%
 4  86.8%  55.9%
Percents determined by Kaplan Meier method
n includes all patients who received at least one day of apheresis
Multiple factors can influence time to engraftment and graft durability following stem cell transplantation. For transplanted patients in the Phase 3 studies, time to neutrophil and platelet engraftment and graft durability were similar across the treatment groups.
16 HOW SUPPLIED/STORAGE AND HANDLING
Each single-use vial is filled to deliver 1.2 mL of 20 mg/mL solution containing 24 mg of plerixafor.
NDC Number: 58468-0140-1
Store at 25oC (77oF); excursions permitted to 15o-30oC (59o-86oF). [see USP Controlled Room temperature]
Each vial of Mozobil is intended for single use only. Any unused drug remaining after injection must be discarded.
17 PATIENT COUNSELING INFORMATION
Advise patients of the signs and symptoms of potential systemic reactions such as urticaria, periorbital swelling, dyspnea, or hypoxia during and following Mozobil injection. [see Adverse Reactions (6.1)]
Patients should inform a health care professional immediately if symptoms of vasovagal reactions such as orthostatic hypotension or syncope occur during or shortly after their Mozobil injection. [see Adverse Reactions (6.1)]
If patients experience itching, rash, or reaction at the site of injection, they should notify a health care professional as these symptoms have been treated with over-the-counter medications during clinical trials. [see Adverse Reactions (6.1)]
Inform patients that Mozobil may cause gastrointestinal disorders, including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Patients should be told how to manage specific gastrointestinal disorders and to inform their health care professional if severe events occur following Mozobil injection. [see Adverse Reactions (6.1)]
Advise female patients with reproductive potential to use effective contraceptive methods during Mozobil use. [see Warnings and Precautions (5.5) and Use In Specific Populations (8.1)]
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56b1b78-0ae2-41b4-9c76-98ad9d439199

责任编辑:admin


相关文章
Neurotropin 3.6 N.U. injection(神经营养因子 N.U.注射剂)
DIPEPTIVEN IV(丙氨酰谷氨酰胺注射液)
GHRP KAKEN 100 Injection(普拉莫瑞林盐酸盐注射剂[注射用GHRP])
LEUPLIN PRO FOR INJECTION KIT(醋酸亮丙瑞林注射用/试剂盒)
Prenoxad Injection(盐酸纳洛酮注射溶液)
Darzalex的三联疗法可延长多发性骨髓瘤生存期
Tiepenem Injection(注射用水合亚胺培南/西司他丁钠)
Nucala injection(美泊利单抗(基因重组)皮下注射液)
CALCICOL Injection 8.5%(葡萄糖酸钙注射剂)
IMUNACE Injection(替西白介素基因重组注射剂)
PEGASYS S.C. Injection(重组聚乙二醇干扰素α-2a皮下注射)
 

最新文章

更多

· Ofev soft capsules(尼...
· REPATHA(evolocumab inj...
· TECENTRIQ(atezolizumab...
· Cabometyx(cabozantinib...
· Nuplazid(Pimavanserin ...
· ZURAMPIC(lesinurad tab...
· PLEGRIDY injection(peg...
· Voluven 6% Injection(中...
· Anthim(Obiltoxaximab I...
· Cinqair(reslizumab)注...

推荐文章

更多

· Ofev soft capsules(尼...
· REPATHA(evolocumab inj...
· TECENTRIQ(atezolizumab...
· Cabometyx(cabozantinib...
· Nuplazid(Pimavanserin ...
· ZURAMPIC(lesinurad tab...
· PLEGRIDY injection(peg...
· Voluven 6% Injection(中...
· Anthim(Obiltoxaximab I...
· Cinqair(reslizumab)注...

热点文章

更多

· REPATHA(evolocumab inj...
· Ofev soft capsules(尼...